Novartis AG Common Stock (NVS)

(BPT) - Key takeaways:

Don't expect earnings day to sustain the stock's recent rally.

Novartis (NYSE:NVS) reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core operating income. Chief Executive Officer Vas Narasimhan said quarterly sales rose 4% in constant curre

Priority brands offset generic erosion as margin expands and pipeline advances.

Novartis stock rose slightly early Tuesday on strong third-quarter income, but the company's biggest moneymaker fell short.

Novartis (NYSE:NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton’s tyrosine kinase inhibitor reduced relapse rates and MRI lesion activity versus teriflunomide in the REMODEL-1 and REMODEL-2 studies. The company said global regulatory

A recent survey shows reasons to be bullish on international stocks. But some global ETFs look more bullish than others.

(BPT) - Key takeaways:

Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains.

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.

The pharmaceutical giant's track record in past bear markets is fairly impressive.

Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.

Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sharp stock declines after trial setbacks.

Crude oil pushed toward $100 per barrel amid Middle East conflict and U.S.-Canada trade friction, today, Sept. 8, 2026.

Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.

Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday.

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.

Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.

Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.

Novartis' Ionis-partnered Lp(a) blocker failed in testing. Both stocks fell.